Clinical Trial Update: IgM-enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis

View source ↗

Summary

A completed clinical trial update suggests that IgM-enriched immunoglobulin reduces systemic endotoxin activity in early severe sepsis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• IgM-enriched immunoglobulin (IgM-enriched immunoglobulin)

Snippet

Sponsor: Goethe University | Conditions: Sepsis | Status: COMPLETED